ArticleFrontiers in public health2025
Health economic evaluation of EV71 vaccination in children under the school-age population in Guangdong Province, China.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Economic evaluation of including the EV71 vaccine in the national immunization program: a modeling study in Guangxi, China.Frontiers in public health · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to evaluate the health economics of hand-foot-mouth disease enterovirus 71 (EV71) vaccination for the population of appropriate age in Guangdong Province. Methods: A SEIR model was constructed, and a group of differential equations was established. The incidence data of HFMD in Guangdong from January to June 2017 were used to fit the model and the basic reproduction value (R Results: The self-funded voluntary EV71 vaccination strategy implemented in Guangdong Province has effectively reduced the disease economic burden of EV71-type HFMD, and the disease economic burden saved during the peak seasonal segment of HFMD in 2017 was $1,080,000. Meanwhile, Scenario 2, 3, and 4 would each result in a cumulative reduction of 6,525, 9,556, and 10,989 confirmed cases, respectively, with net monetary benefits of approximately $6.55 million, $9.59 million, and $11.2 million. The study results show that the current vaccine pricing is not cost-effectiveness, while the vaccine price is lower than $13.15, EV71 vaccination in Guangdong Province has a cost-effectiveness advantage. Conclusion: Vaccination can reduce the incidence of HFMD caused by EV71, which helps to improve the status of HFMD and decreases the disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.